HemaSphere (Aug 2023)
PB2131: MAGNETISMM-7: AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF ELRANATAMAB VERSUS LENALIDOMIDE IN POST-TRANSPLANT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
Abstract
No abstracts available.
HemaSphere (Aug 2023)